PIA
RYTM icon

Piedmont Investment Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Piedmont Investment Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-213
Closed -$7K – 2041
2018
Q2 		$7K Buy
+213
New +$5.82K ﹤0.01% 1988

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Piedmont Investment Advisors's RYTM Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2018, closing a stake of 213 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in RYTM in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 78 funds tracked by Wall St. Rank hold RYTM as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Rhythm Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 213 Rhythm Pharmaceuticals shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Rhythm Pharmaceuticals position peaked at $7K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.